Notizie e Video - DIURNAL GRP. ORD GBP0.05

SVM Asset Management - Form 8.3 - Diurnal Group plc PR Newswire London, August 31 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SVM Asset Management Ltd (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a...

Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc 30-Aug-2022 / 12:32 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full...

EffRx Pharmaceuticals SA, une société de phase commerciale qui met sur le marché des médicaments pour des indications niches et orphelines en Suisse et en Europe, annonce avoir récemment conclu un accord de licence exclusif avec Diurnal Group plc, pour l'enregistrement et la mise sur le marché d'Efmody ® dans le traitement de l'hyperplasie congénitale des surrénales (HCS) en Suisse. En vertu des clauses de l'accord, EffRx a reçu les droits exclusifs pour enregistrer et commercialiser...

IRLAB Therapeutics AB is dedicated to the discovery and development of new drugs for treatment of Parkinson's disease and ......

MENLO PARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI ® Surgical System suppressed daily fluctuations in intraocular pressure (IOP) – a meaningful and independent risk factor for...

Hardman & Co Research Hardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum 07-Oct-2021 / 11:15 GMT/BST Hardman & Co Life Sciences Investor Forum company research: Diurnal Group (DNL) On 23 September we were delighted to host our second Life Sciences Investor Forum. At the live event, CEO, Martin Whitaker, answered questions on the business growth and M&A plans for Diurnal's portfolio as well the commercial rights to Chronocort (R) in the US and the expected changes when the drug is...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials 16-Sep-2021 / 10:15 GMT/BST Hardman & Co Research: All set for three pivotal trials Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader. Alkindi(R), soon to be accompanied by Efmody(R), continues to be rolled out throughout...

Hardman & Co Research Hardman & Co Video Event | Diurnal Group plc - Investor Forum 12-Aug-2021 / 07:20 GMT/BST Hardman & Co Video Event | Diurnal Group plc Investor Forum We are delighted to announce that Diurnal Group plc will be presenting at our next Investor Forum on Thursday 23 September at 5:00pm. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A. The Forum is being hosted by Hardman &...

Edison Investment Research Limited Edison Investment Research Limited: Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders 15-March-2021 / 07:00 GMT/BST London, UK, 15 March 2021 Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders We are initiating coverage on Diurnal Group, which is developing and commercialising multiple products from the class of steroid hormones. The company's first product, Alkindi, is marketed in the United States and...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R) 25-Feb-2021 / 07:15 GMT/BST Hardman & Co Research: Attention turning to Chronocort(R) Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) is being rolled out by Diurnal throughout Europe and has been...

Hardman & Co Research Hardman & Co Research: Diurnal (DNL): And then there were three 30-Sep-2020 / 08:15 GMT/BST Hardman & Co Research: And then there were three Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) was approved by the European regulators in September 2018, and has been...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators 17-Sep-2020 / 12:40 GMT/BST Hardman & Co Research: Closely watching the regulators Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) is being rolled out throughout Europe, and recent approvals...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall 20-Aug-2020 / 07:15 GMT/BST Hardman & Co Research: Q&A with Dr Martin Hall Diurnal Group plc (LON:DNL) is the topic of conversation when Hardman & Co Analyst Martin Hall joins DirectorsTalk. Martin talks us through some of the more interesting newsflow items, expands on the significance of the US partnering deal with Eton, the more recent Alkindi approvals, what we can expect from 2020/21 and shares his...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals 13-Aug-2020 / 07:15 GMT/BST Hardman & Co Research: Flow of regulatory approvals Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) is currently being rolled out throughout Europe, and recent...

Hardman & Co Research Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further 30-March-2020 / 15:05 GMT/BST Hardman & Co Res earch : $52.5m US deal strengthens balance sheet further Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Alkindi (R) is currently being...

Hardman & Co Research Hardman & Co Research: Diurnal (DNL): . and more to come (news flow) 28-Feb-2020 / 07:30 GMT/BST Hardman & Co Res earch : . and more to come (news flow) Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Its first drug, Alkindi, is being rolled out through key...

Hardman & Co Research Hardman & Co Research: Diurnal (DNL): Successful DITEST Phase I trial outcome 26-Nov-2019 / 07:15 GMT/BST Hardman & Co Res earch : Successful DITEST Phase I trial outcome Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort , are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful outcome of the Phase I trial with DITEST, an oral...

Hardman & Co Research Hardman & Co Research: Diurnal (DNL): Approaching a number of near-term milestones 05-Nov-2019 / 07:30 GMT/BST Hardman & Co Res earch : Approaching a number of near-term milestones Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term 'Adrenal Franchise'. The first product, Alkindi (R), is...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway 25-Apr-2019 / 07:15 GMT/BST Hardman & Co: Clarity for Chronocort regulatory pathway Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term 'Adrenal Franchise'. The first product, Alkindi(R), is being...

Hardman & Co Research Hardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice 16-Jan-2019 / 07:15 GMT/BST Hardman & Co Research: Chronocort - seeking regulatory advice Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Alkindi is being launched in key EU markets,...